Principal publications

A variety of books Principal publications from the Bladder Cancer Research Centre

Bladder Cancer Research Centre-led original research

Properties of non-coding mutation hotspots as urinary biomarkers for bladder cancer detection. Baxter L, Gordon NS, Ott S, Wang J, Patel P, Goel A, Piechocki K, Silcock L, Sale C, Zeegers MP, Cheng KK, James ND; BladderPath trial management group; Bryan RT, Ward DG. Sci Rep. 2023 Jan 19;13(1):1060. doi: 10.1038/s41598-023-27675-4. PMID: 36658180
Combined exome and transcriptome sequencing of non-muscle-invasive bladder cancer: associations between genomic changes, expression subtypes and clinical outcomes. Goel A, Ward DG, Noyvert B, Yu M, Gordon NS, Abbotts B, Colbourne JK, Kissane S, James ND, Zeegers MP, Cheng KK, Cazier JB, Whalley CM, Beggs AD, Palles C, Arnold R, Bryan RT. Genome Med. 2022 Jun 3;14(1):59. doi: 10.1186/s13073-022-01056-4. PMID: 35655252

Highly Sensitive and Specific Detection of Bladder Cancer via Targeted Ultra-deep Sequencing of Urinary DNA. Ward DG, Baxter L, Ott S, Gordon NS, Wang J, Patel P, Piechocki K, Silcock L, Sale C, Zeegers MP, Cheng KK, James ND, Bryan RT; BladderPath Trial Management Group. Eur Urol Oncol. 2023 Feb;6(1):67-75. doi: 10.1016/j.euo.2022.03.005. Epub 2022 Apr 8. PMID: 35410825
STAG2 Protein Expression in Non-muscle-invasive Bladder Cancer: Associations with Sex, Genomic and Transcriptomic Changes, and Clinical Outcomes. Gordon NS, Humayun-Zakaria N, Goel A, Abbotts B, Zeegers MP, Cheng KK, James ND, Arnold R, Bryan RT, Ward DG. Eur Urol Open Sci. 2022 Mar 4;38:88-95. doi: 10.1016/j.euros.2022. 02.004. eCollection 2022 Apr. PMID: 35495284
Urine DNA for monitoring chemoradiotherapy response in muscle-invasive bladder cancer: a pilot study. Gordon NS, Baxter LA, Goel A, Arnold R, Kaur B, Liu W, Pirrie SJ, Hussain S, Viney R, Ford D, Zarkar A, Wood MA, Mitin T, Thompson RF, James ND, Ward DG, Bryan RT. BJU Int. 2022 Jan;129(1):32-34. doi: 10.1111/bju.15589. Epub 2021 Sep 20. PMID: 34491610 No abstract available.
Comparing an Imaging-guided Pathway with the Standard Pathway for Staging Muscle-invasive Bladder Cancer: Preliminary Data from the BladderPath Study. Bryan RT, Liu W, Pirrie SJ, Amir R, Gallagher J, Hughes AI, Jefferson KP, Knight A, Nanton V, Mintz HP, Pope AM, Catto JWF, Patel P, James ND. Eur Urol. 2021 Jul;80(1):12-15. doi: 10.1016/ j.eururo.2021.02.021. Epub 2021 Feb 27. PMID: 33653635
PD-L2 Is Constitutively Expressed in Normal and Malignant Urothelium. Dowell AC, Munford H, Goel A, Gordon NS, James ND, Cheng KK, Zeegers MP, Ward DG, Bryan RT. Front Oncol. 2021 Feb 25;11:626748. doi: 10.3389/fonc.2021.626748. eCollection 2021. PMID: 33718196
Prognostic DNA Methylation Biomarkers in High-risk Non-muscle-invasive Bladder Cancer: A Systematic Review to Identify Loci for Prospective Validation. Gurung PMS, Barnett AR, Wilson JS, Hudson J, Ward DG, Messing EM, Bryan RT. Eur Urol Focus. 2020 Jul 15;6(4):683-697. doi: 10.1016/j.euf.2019.02.012. Epub 2019 Feb 23. PMID: 30803927
Gene-environment interaction with smoking for increased non-muscle-invasive bladder cancer tumor size. Lipunova N, Wesselius A, Cheng KK, van Schooten FJ, Bryan RT, Cazier JB, Zeegers MP. Transl Androl Urol. 2020 Jun;9(3):1329-1337. doi: 10.21037/tau-19-523. PMID: 32676417
Back-Splicing Transcript Isoforms (Circular RNAs) Affect Biologically Relevant Pathways and Offer an Additional Layer of Information to Stratify NMIBC Patients. Goel A, Ward DG, Gordon NS, Abbotts B, Zeegers MP, Cheng KK, James ND, Bryan RT, Arnold R. Front Oncol. 2020 May 22;10:812. doi: 10.3389/fonc.2020.00812. eCollection 2020. PMID: 32670866
Fluid intake and clinicopathological characteristics of bladder cancer: the West Midlands Bladder Cancer Prognosis Programme. van Hensbergen M, van Osch FHM, Jochems S, James ND, Wallace DMA, Wesselius A, Cheng KK, Bryan RT, Zeegers MP. Eur J Cancer Prev. 2020 Mar;29(2):110-118. doi: 10.1097/CEJ. 0000000000000525. PMID: 32012137
Systematic Review: Genetic Associations for Prognostic Factors of Urinary Bladder Cancer. Lipunova N, Wesselius A, Cheng KK, van Schooten FJ, Cazier JB, Bryan RT, Zeegers MP. Biomark Cancer. 2019 Dec 30;11:1179299X19897255. doi: 10.1177/1179299X19897255. eCollection 2019. PMID: 31908559 Review.
Health-related quality of life around the time of diagnosis in patients with bladder cancer. Yu EY, Nekeman D, Billingham LJ, James ND, Cheng KK, Bryan RT, Wesselius A, Zeegers MP. BJU Int. 2019 Dec;124(6):984-991. doi: 10.1111/bju.14804. Epub 2019 Jun 7. PMID: 31077532
Patients choose certainty over burden in bladder cancer surveillance. van Osch FHM, Nekeman D, Aaronson NK, Billingham LJ, James ND, Cheng KK, Bryan RT, Zeegers MP. World J Urol. 2019 Dec;37(12):2747-2753. doi: 10.1007/s00345-019-02728-4. Epub 2019 Mar 23. PMID: 30903352
Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification. Ward DG, Gordon NS, Boucher RH, Pirrie SJ, Baxter L, Ott S, Silcock L, Whalley CM, Stockton JD, Beggs AD, Griffiths M, Abbotts B, Ijakipour H, Latheef FN, Robinson RA, White AJ, James ND, Zeegers MP, Cheng KK, Bryan RT. BJU Int. 2019 Sep;124(3):532-544. doi: 10.1111/bju. 14808. Epub 2019 Jun 19. PMID: 31077629
Genome-wide Association Study for Tumour Stage, Grade, Size, and Age at Diagnosis of Non-muscle-invasive Bladder Cancer. Lipunova N, Wesselius A, Cheng KK, van Schooten FJ, Bryan RT, Cazier JB, Galesloot TE, Kiemeney LALM, Zeegers MP. Eur Urol Oncol. 2019 Jul;2(4):381-389. doi: 10.1016/j.euo. 2018.08.020. Epub 2018 Sep 15. PMID: 31277774
Tar, nicotine and carbon monoxide yield of UK cigarettes and the risk of non-muscle-invasive and muscle-invasive bladder cancer. van Osch FHM, Pauwels CGGM, Jochems SHJ, Fayokun R, James ND, Wallace DMA, Cheng KK, Bryan RT, van Schooten FJ, Zeegers MP. Eur J Cancer Prev. 2019 Jan;28(1):40-44. doi: 10.1097/CEJ.0000000000000404. PMID: 28683008
Non-Coding Mutations in Urothelial Bladder Cancer: Biological and Clinical Relevance and Potential Utility as Biomarkers Jeeta RR, Gordon NS, Baxter L, Goel A, Noyvert B, Ott S, Boucher RH, Humayun-Zakaria N, Arnold R, James ND, Zeegers MP, Cheng KK, Bryan RT, Ward DG. Bladder Cancer. 2019 5(4): 263-272. DOI: 10.3233/BLC-190251.
Total Fluid Intake and the Risk of Recurrence in Patients With Non-Muscle Invasive Bladder Cancer: A Prospective Cohort Study. Jochems SHJ, van Osch FHM, Reulen RC, van Hensbergen M, Nekeman D, Pirrie SJ, Wesselius A, van Schooten FJ, James ND, Wallace DMA, Bryan RT, Cheng KK, Zeegers MP. Bladder Cancer. 2018 Jul 30;4(3):303-310. doi: 10.3233/BLC-180172. PMID: 30112441
Defining the frequency of human papillomavirus and polyomavirus infection in urothelial bladder tumours. Llewellyn MA, Gordon NS, Abbotts B, James ND, Zeegers MP, Cheng KK, Macdonald A, Roberts S, Parish JL, Ward DG, Bryan RT. Sci Rep. 2018 Jul 26;8(1):11290. doi: 10.1038/s41598-018-29438-y. PMID: 30050097
The association between smoking cessation before and after diagnosis and non-muscle-invasive bladder cancer recurrence: a prospective cohort study. van Osch FHM, Jochems SHJ, Reulen RC, Pirrie SJ, Nekeman D, Wesselius A, James ND, Wallace DMA, Cheng KK, van Schooten FJ, Bryan RT, Zeegers MP. Cancer Causes Control. 2018 Jul;29(7):675-683. doi: 10.1007/s10552-018-1046-8. Epub 2018 May 30. PMID: 29846846
Fruit and vegetable intake and the risk of recurrence in patients with non-muscle invasive bladder cancer: a prospective cohort study. Jochems SHJ, van Osch FHM, Reulen RC, van Hensbergen M, Nekeman D, Pirrie S, Wesselius A, van Schooten FJ, James ND, Wallace DMA, Bryan RT, Cheng KK, Zeegers MP. Cancer Causes Control. 2018 Jun;29(6):573-579. doi: 10.1007/s10552-018-1029-9. Epub 2018 Apr 17. PMID: 29667104
Exploring the roles of urinary HAI-1, EpCAM & EGFR in bladder cancer prognosis & risk stratification. Snell KIE, Ward DG, Gordon NS, Goldsmith JC, Sutton AJ, Patel P, James ND, Zeegers MP, Cheng KK, Bryan RT. Oncotarget. 2018 May 18;9(38):25244-25253. doi: 10.18632/oncotarget. 25397. eCollection 2018 May 18. PMID: 29861867
Centralisation of radical cystectomies for bladder cancer in England, a decade on from the 'Improving Outcomes Guidance': the case for super centralisation. Afshar M, Goodfellow H, Jackson-Spence F, Evison F, Parkin J, Bryan RT, Parsons H, James ND, Patel P. BJU Int. 2018 Feb;121(2):217-224. doi: 10.1111/bju.13929. Epub 2017 Jul 10. PMID: 28594471
Toward Personalised Liquid Biopsies for Urothelial Carcinoma: Characterisation of ddPCR and Urinary cfDNA for the Detection of the TERT 228 G>A/T Mutation. Russo IJ, Ju Y, Gordon NS, Zeegers MP, Cheng KK, James ND, Bryan RT, Ward DG. Bladder Cancer. 2018 Jan 20;4(1):41-48. doi: 10.3233/BLC-170152. PMID: 29430506
Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer. Dowell AC, Cobby E, Wen K, Devall AJ, During V, Anderson J, James ND, Cheng KK, Zeegers MP, Bryan RT, Taylor GS. PLoS One. 2017 Sep 20;12(9):e0184841. doi: 10.1371/journal.pone. 0184841. eCollection 2017. PMID: 28931051
Multiplex screening of 422 candidate serum biomarkers in bladder cancer patients identifies syndecan-1 and macrophage colony-stimulating factor 1 as prognostic indicators Bryan RT, Gordon NS, Abbotts B , Zeegers MP, Cheng KK, James ND, Ward DG. Transl Cancer Res 2017;6(Suppl 4):S657-S665 doi: 10.21037/tcr.2017.04.19
Prediction of histological stage based on cystoscopic appearances of newly diagnosed bladder tumours. During VA, Sole GM, Jha AK, Anderson JA, Bryan RT. Ann R Coll Surg Engl. 2016 Nov; 98(8):547-551. doi: 10.1308/rcsann.2016.0246. Epub 2016 Aug 9. PMID: 27502337
Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA. Togneri FS, Ward DG, Foster JM, Devall AJ, Wojtowicz P, Alyas S, Vasques FR, Oumie A, James ND, Cheng KK, Zeegers MP, Deshmukh N, O'Sullivan B, Taniere P, Spink KG, McMullan DJ, Griffiths M, Bryan RT. Eur J Hum Genet. 2016 Aug;24(8):1167-74. doi: 10.1038/ejhg.2015.281. Epub 2016 Jan 13. PMID: 26757983
Viscoelastic properties of human bladder tumours. Barnes SC, Lawless BM, Shepherd DET, Espino DM, Bicknell GR, Bryan RT. J Mech Behav Biomed Mater. 2016 Aug;61:250-257. doi: 10.1016/j.jmbbm.2016.03.012. Epub 2016 Mar 24. PMID: 27082128
A Systematic Review of the Diagnostic and Prognostic Value of Urinary Protein Biomarkers in Urothelial Bladder Cancer. D'Costa JJ, Goldsmith JC, Wilson JS, Bryan RT, Ward DG. Bladder Cancer. 2016 Jul 27; 2(3):301-317. doi: 10.3233/BLC-160054. PMID: 27500198
Design of an improved surgical instrument for the removal of bladder tumours. Barnes SC, Shepherd DE, Espino DM, Bryan RT, Viney R, Patel P. Proc Inst Mech Eng H. 2016 Jun;230(6):579-87. doi: 10.1177/0954411916640580. Epub 2016 Apr 12. PMID: 27075816
Multiplex PCR and Next Generation Sequencing for the Non-Invasive Detection of Bladder Cancer. Ward DG, Baxter L, Gordon NS, Ott S, Savage RS, Beggs AD, James JD, Lickiss J, Green S, Wallis Y, Wei W, James ND, Zeegers MP, Cheng KK, Mathews GM, Patel P, Griffiths M, Bryan RT. PLoS One. 2016 Feb 22;11(2):e0149756. doi: 10.1371/journal.pone.0149756. eCollection 2016. PMID: 26901314
Use of Aleuria alantia Lectin Affinity Chromatography to Enrich Candidate Biomarkers from the Urine of Patients with Bladder Cancer. Ambrose SR, Gordon NS, Goldsmith JC, Wei W, Zeegers MP, James ND, Knowles MA, Bryan RT, Ward DG. Proteomes. 2015 Sep 3;3(3):266-282. doi: 10.3390/proteomes3030266. PMID: 28248271
A Comparative Analysis of the Influence of Gender, Pathway Delays, and Risk Factor Exposures on the Long-term Outcomes of Bladder Cancer. Bryan RT, Evans T, Dunn JA, Iqbal G, Bathers S, Collins SI, James ND, Catto JWF, Wallace DMA. Eur Urol Focus. 2015 Aug;1(1):82-89. doi: 10.1016/j.euf.2015.01.001. Epub 2015 May 19. PMID: 28723362
Protein shedding in urothelial bladder cancer: prognostic implications of soluble urinary EGFR and EpCAM. Bryan RT, Regan HL, Pirrie SJ, Devall AJ, Cheng KK, Zeegers MP, James ND, Knowles MA, Ward DG. Br J Cancer. 2015 Mar 17;112(6):1052-8. doi: 10.1038/bjc.2015.21. PMID: 25719831
Urinary EpCAM in urothelial bladder cancer patients: characterisation and evaluation of biomarker potential. Bryan RT, Shimwell NJ, Wei W, Devall AJ, Pirrie SJ, James ND, Zeegers MP, Cheng KK, Martin A, Ward DG. Br J Cancer. 2014 Feb 4;110(3):679-85. doi: 10.1038/bjc.2013.744. Epub 2013 Nov 28. PMID: 24292452
A comparison of patient and tumour characteristics in two UK bladder cancer cohorts separated by 20 years. Bryan RT, Zeegers MP, van Roekel EH, Bird D, Grant MR, Dunn JA, Bathers S, Iqbal G, Khan HS, Collins SI, Howman A, Deshmukh NS, James ND, Cheng KK, Wallace DM. BJU Int. 2013 Jul;112(2):169-75. doi: 10.1111/bju.12032. Epub 2013 Mar 4. PMID: 23452262
Smoking is associated with lower age, higher grade, higher stage, and larger size of malignant bladder tumors at diagnosis. van Roekel EH, Cheng KK, James ND, Wallace DM, Billingham LJ, Murray PG, Bryan RT, Zeegers MP. Int J Cancer. 2013 Jul 15;133(2):446-54. doi: 10.1002/ijc.28017. Epub 2013 Feb 13. PMID: 23292999
Combined proteome and transcriptome analyses for the discovery of urinary biomarkers for urothelial carcinoma. Shimwell NJ, Bryan RT, Wei W, James ND, Cheng KK, Zeegers MP, Johnson PJ, Martin A, Ward DG. Br J Cancer. 2013 May 14;108(9):1854-61. doi: 10.1038/bjc.2013.157. Epub 2013 Apr 16. PMID: 23591195
Assessment of high-throughput high-resolution MALDI-TOF-MS of urinary peptides for the detection of muscle-invasive bladder cancer. Bryan RT, Wei W, Shimwell NJ, Collins SI, Hussain SA, Billingham LJ, Murray PG, Deshmukh N, James ND, Wallace DM, Johnson PJ, Zeegers MP, Cheng KK, Martin A, Ward DG. Proteomics Clin Appl. 2011 Oct;5(9-10):493-503. doi: 10.1002/prca.201100011. Epub 2011 Sep 6. PMID: 21805675
The West Midlands Bladder Cancer Prognosis Programme: rationale and design. Zeegers MP, Bryan RT, Langford C, Billingham L, Murray P, Deshmukh NS, Hussain S, James N, Wallace DM, Cheng KK. BJU Int. 2010 Mar;105(6):784-8. doi: 10.1111/j.1464-410X. 2009.08849.x. Epub 2009 Sep 14. PMID: 19751260
Narrow-band imaging flexible cystoscopy: a new user's experience. Bryan RT, Shah ZH, Collins SI, Wallace DM. J Endourol. 2010 Aug;24(8):1339-43. doi: 10.1089/ end.2009.0598. PMID: 20629569
Cadherin switching dictates the biology of transitional cell carcinoma of the bladder: ex vivo and in vitro studies. Bryan RT, Atherfold PA, Yeo Y, Jones LJ, Harrison RF, Wallace DM, Jankowski JA. J Pathol. 2008 Jun;215(2):184-94. doi: 10.1002/path.2346. PMID: 18393367
Narrow-band imaging flexible cystoscopy in the detection of recurrent urothelial cancer of the bladder. Bryan RT, Billingham LJ, Wallace DM. BJU Int. 2008 Mar;101(6):702-5; discussion 705-6. doi: 10.1111/j.1464-410X.2007.07317.x. Epub 2007 Nov 13. PMID: 18005206
Socio-economic deprivation and survival in bladder cancer. Begum G, Dunn JA, Bryan RT, Bathers S, Wallace DM; West Midlands Urological Research Group. BJU Int. 2004 Sep;94(4):539-43. doi: 10.1111/j.1464-410X.2004.04997.x. PMID: 15329108
The role of beta-catenin signaling in the malignant potential of cystitis glandularis. Bryan RT, Nicholls JH, Harrison RF, Jankowski JA, Wallace DM. J Urol. 2003 Nov;170(5):1892-6. doi: 10.1097/01.ju.0000092740.51330.39. PMID: 14532801
Delay and survival in bladder cancer. Wallace DM, Bryan RT, Dunn JA, Begum G, Bathers S; West Midlands Urological Research Group. BJU Int. 2002 Jun;89(9):868-78. doi: 10.1046/j.1464-410x.2002.02776.x. PMID: 12010230

Bladder Cancer Research Centre-led reviews and editorials

Novel intravesical therapeutics in the treatment of non-muscle invasive bladder cancer: Horizon scanning. Ward K, Kitchen MO, Mathias SJ, Khanim FL, Bryan RT. Front Surg. 2022 Jul 26;9:912438. doi: 10.3389/fsurg.2022.912438. eCollection 2022. PMID: 35959122 Review.
Immunotherapy for non-muscle-invasive bladder cancer: from the origins of BCG to novel therapies. Unsworth-White SR, Kitchen MO, Bryan RT. Future Oncol. 2022 Jan;18(1):105-115. doi: 10.2217/ fon-2021-0781. Epub 2021 Nov 12. PMID: 34763531
The Sirenic Links between Diabetes, Obesity, and Bladder Cancer. Gill E, Sandhu G, Ward DG, Perks CM, Bryan RT. Int J Mol Sci. 2021 Oct 15;22(20):11150. doi: 10.3390/ijms222011150. PMID: 34681810 Review.
Reply to Trey Durdin, Alvin Goh, and Eugene Pietzak. Can an Imaging-guided Pathway Replace the Current Paradigm for Muscle-invasive Bladder Cancer? Bryan RT, Catto JWF, Jefferson KP, Patel P, James ND, On Behalf Of The BladderPath Trial Management Group. Eur Urol. 2021 Jul;80(1):18-19. doi: 10.1016/j.eururo.2021.04.034. Epub 2021 May 8. PMID: 33972095 No abstract available.
Trends in urine biomarker discovery for urothelial bladder cancer: DNA, RNA, or protein? Humayun-Zakaria N, Ward DG, Arnold R, Bryan RT. Transl Androl Urol. 2021 Jun;10(6):2787-2808. doi: 10.21037/tau-20-1327. PMID: 34295762 Review.
Establishing the Bladder Cancer Research Centre at the University of Birmingham. Bryan RT, Arnold R, Khanim FL, Shepherd DE, Patel P, Ward DG. Nat Rev Urol. 2021 Jun;18(6):318-320. doi: 10.1038/s41585-021-00448-2. PMID: 33712734.
Molecular Subtypes of T1 Bladder Cancer: Biomolecular Characteristics Versus Clinical Utility. Ward DG, Arnold R, Bryan RT. Eur Urol. 2020 Oct;78(4):538-539. doi: 10.1016/j.eururo. 2020.07.021. Epub 2020 Aug 6. PMID: 32773351.
Microscopic Haematuria and Significant Urinary Tract Disease Bryan RT, Kockelbergh RC. Bladder Cancer. 2019 Aug 16;5(2): 115–117 doi 10.3233/BLC-199006
Tropomyosins: Potential Biomarkers for Urothelial Bladder Cancer. Humayun-Zakaria N, Arnold R, Goel A, Ward D, Savill S, Bryan RT. Int J Mol Sci. 2019 Mar 4;20(5):1102. doi: 10.3390/ijms20051102. PMID: 30836651 Review.
Massively parallel sequencing of urinary DNA—the dawn of non-invasive bladder cancer detection and surveillance? Ward DG, Bryan, RT. Transl Cancer Res. 2019 Mar;8(Suppl 2):S204-S207. doi: 10.21037/tcr. 2019.03.03. PMID: 35117098
Association between treatment of superficial bladder cancer and 10-year mortality in older adults with multiple chronic conditions. Bryan RT. Cancer. 2019 Feb 15;125(4):652. doi: 10.1002/cncr.31888. Epub 2018 Dec 5. PMID: 30516824.
Red patches during bladder cancer surveillance: to biopsy or not to biopsy? Drejer D, Jensen JB, Bryan RT. Transl Androl Urol. 2018 Apr;7(2):280-282. doi: 10.21037/ tau.2018.03.10. PMID: 29733089
Liquid biopsies for bladder cancer. Ward DG, Bryan RT. Transl Androl Urol. 2017 Apr;6(2):331-335. doi: 10.21037/tau.2017.03.08. PMID: 28540249
The PD-1/PD-L1 axis in the pathogenesis of urothelial bladder cancer and evaluating its potential as a therapeutic target. Bardoli AD, Afshar M, Viney R, Foster M, Porfiri E, Zarkar A, Stevenson R, James ND, Bryan RT, Patel P. Future Oncol. 2016 Mar;12(5):595-600. doi: 10.2217/fon.15.337. Epub 2016 Feb 1. PMID: 26880382 Review. No abstract available.
Words of wisdom. Bladder cancers arise from distinct urothelial sub-populations. Bryan RT, Ward DG. Eur Urol. 2015 Mar;67(3):590-1. doi: 10.1016/j.eururo.2014.11.058. PMID: 25760413
Cell adhesion and urothelial bladder cancer: the role of cadherin switching and related phenomena. Bryan RT. Philos Trans R Soc Lond B Biol Sci. 2015 Feb 5;370(1661):20140042. doi: 10.1098/ rstb.2014.0042. PMID: 25533099 Review.
The effects and effectiveness of electromotive drug administration and chemohyperthermia for treating non-muscle invasive bladder cancer. Slater SE, Patel P, Viney R, Foster M, Porfiri E, James ND, Montgomery B, Bryan RT. Ann R Coll Surg Engl. 2014 Sep;96(6):415-9. doi: 10.1308/003588414X13946184901001. PMID: 25198970 Review.
Does the nonurologic scientific community understand urothelial bladder cancer? Bryan RT, Kirby R, Mostafid H. Eur Urol. 2014 Sep;66(3):601-2. doi: 10.1016/j.eururo.2014. 04.010. Epub 2014 May 10. PMID: 24821580
So much cost, such little progress. Bryan RT, Kirby R, O'Brien T, Mostafid H. Eur Urol. 2014 Aug;66(2):263-4. doi: 10.1016/ j.eururo.2014.02.031. Epub 2014 Feb 22. PMID: 24598013
Cytokines as effectors and predictors of responses in the treatment of bladder cancer by bacillus Calmette-Guérin. Liu X, Dowell AC, Patel P, Viney RP, Foster MC, Porfiri E, James ND, Bryan RT. Future Oncol. 2014 Jun;10(8):1443-56. doi: 10.2217/fon.14.79. PMID: 25052754 Review.
Optimising existing therapeutic strategies for the treatment of non-muscle-invasive bladder cancer: the role of intensive neoadjuvant intravesical mitomycin C. Bryan RT. Eur Urol. 2012 Nov;62(5):803-5. doi: 10.1016/j.eururo.2012.06.023. Epub 2012 Jun 15. PMID: 22728115 No abstract available.
Emerging endoscopic and photodynamic techniques for bladder cancer detection and surveillance. Patel P, Bryan RT, Wallace DM. ScientificWorldJournal. 2011;11:2550-8. doi: 10.1100/2011/ 412739. Epub 2011 Dec 29. PMID: 22235185 Review.
Bladder cancer: time for a rethink? Bryan RT, James ND. Oncology (Williston Park). 2011 Sep;25(10):965, 968. PMID: 22010397
Bladder cancer and cancer stem cells: basic science and implications for therapy. Bryan RT. ScientificWorldJournal. 2011 Jun 9;11:1187-94. doi: 10.1100/tsw.2011.117. PMID: 21666988 Review.
Mechanisms of recurrence of Ta/T1 bladder cancer. Bryan RT, Collins SI, Daykin MC, Zeegers MP, Cheng KK, Wallace DM, Sole GM. Ann R Coll Surg Engl. 2010 Sep;92(6):519-24. doi: 10.1308/003588410X12664192076935. Epub 2010 Jun 1. PMID: 20522307
Cadherin switching and bladder cancer. Bryan RT, Tselepis C. J Urol. 2010 Aug;184(2):423-31. doi: 10.1016/j.juro.2010.04.016. Epub 2010 Jun 17. PMID: 20620393 Review.
Is it time to re-design the haematuria clinic? Bryan RT, Wallace MA. BJU Int. 2010 May;105(10):1478-9; author reply 1479. doi: 10.1111/ j.1464-410X.2010.09395_1.x. PMID: 20518770 No abstract available.
Biomarkers in bladder cancer. Bryan RT, Zeegers MP, James ND, Wallace DM, Cheng KK. BJU Int. 2010 Mar;105(5):608-13. doi: 10.1111/j.1464-410X.2009.08880.x. Epub 2009 Sep 29. PMID: 19793380 Review.
Editorial comment on: Nocturia frequency, bother, and quality of life: how often is too often? A population-based study in Finland. Bryan RT, Zeegers MP. Eur Urol. 2010 Mar;57(3):496-7. doi: 10.1016/j.eururo.2009.03.081. Epub 2009 Apr 3. PMID: 19361913 No abstract available.
Have we abandoned the "superficial" in bladder cancer? Bryan RT, Wallace DM. Eur Urol. 2009 Dec;56(6):1091. doi: 10.1016/j.eururo.2009.03.051. Epub 2009 Mar 31. PMID: 19345470 No abstract available.
Re: Palou et al.: Recurrence at three months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors. (Urology 2009;73:1313-1317). Bryan RT, Cheng KK, Wallace DM. Urology. 2009 Sep;74(3):714. doi: 10.1016/j.urology. 2009.06.010. PMID: 19716932
Editorial comment on: A new generation of optical diagnostics for bladder cancer: technology, diagnostic accuracy, and future applications. Bryan RT. Eur Urol. 2009 Aug;56(2):297. doi: 10.1016/j.eururo.2009.02.039. Epub 2009 Mar 13. PMID: 19285786 No abstract available.
Molecular pathways in bladder cancer: part 1. Bryan RT, Hussain SA, James ND, Jankowski JA, Wallace DM. BJU Int. 2005 Mar;95(4):485-90. doi: 10.1111/j.1464-410X.2005.05325.x. PMID: 15705065 Review.
Molecular pathways in bladder cancer: part 2. Bryan RT, Hussain SA, James ND, Jankowski JA, Wallace DM. BJU Int. 2005 Mar;95(4):491-6. doi: 10.1111/j.1464-410X.2005.05326.x. PMID: 15705066 Review.
'Superficial' bladder cancer - time to uncouple pT1 tumours from pTa tumours. Bryan RT, Wallace DM. BJU Int. 2002 Dec;90(9):846-52. doi: 10.1046/j.1464-410x.2002. 03053.x. PMID: 12460344 Review.

BCRC research with partners and collaborators

Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer. Kerzeli IK, Kostakis A, Türker P, Malmström PU, Hemdan T, Mezheyeuski A, Ward DG, Bryan RT, Segersten U, Lord M, Mangsbo SM. BMC Cancer. 2023 Jun 30;23(1):605. doi: 10.1186/ s12885-023-11100-0. PMID: 37391708
An Association Study of Germline Variants in Bladder Cancer-Related Genes with the Prognosis of Non-Muscle Invasive Bladder Cancer. Hof JP, Vermeulen SH, van der Heijden AG, Verhaegh GW, Dyrskjøt L, Catto JWF, Mengual L, Bryan RT, Fleshner NE, Kiemeney LAML, Galesloot TE. Bladder Cancer 2023 Mar 6: 1-13 doi: 10.3233/BLC-220076

Evidence or Prejudice? Critical Re-Analysis of Randomized Controlled Trials Comparing Overall Survival After Cisplatin Versus Carboplatin-Based Regimens in Advanced Urothelial Carcinoma. Richters A, Kiemeney LALM, Mehra N, Westgeest HM, Birtle A, Bryan RT, Aben KKH. Clin Genitourin Cancer. 2022 Aug;20(4):e346-e352. doi: 10.1016/j.clgc.2021.12.017. Epub 2021 Dec 27. PMID: 35039230

The experience of UK patients with bladder cancer during the second wave of the COVID-19 pandemic. Russell B, Spencer-Bowdage S, Rigby J, O'Kelly J, Kelly P, Page M, Raw C, Allchorne P, Harper P, Crew J, Kockelbergh R, Knight A, Van Hemelrijck M, Bryan RT. BJUI Compass. 2022 May 17;3(5):324-326. doi: 10.1002/bco2.153. eCollection 2022 Sep. PMID: 35945948
Scoping review: bladder cancer in Nigeria - what are the gaps in clinical care and research? Iya AM, Beyer K, Kotecha P, Kibaru J, Abdullahi M, Alhassan SU, Mustapha MI, Ahmad A, Lawal Y, Rabiu Ibrahim J, Aminu A, Abubakar A, Saleh A, Bryan RT, Van Hemelrijck M, Russell B. BMJ Open. 2022 Mar 8;12(3):e049241. doi: 10.1136/bmjopen-2021-049241. PMID: 35260447
Genome-wide Meta-analysis Identifies Novel Genes Associated with Recurrence and Progression in Non-muscle-invasive Bladder Cancer. Galesloot TE, Grotenhuis AJ, Kolev D, Aben KK, Bryan RT, Catto JWF, Cheng KK, Conroy S, Dyrskjøt L, Fleshner NE, James ND, Lamy P, Lindskrog SV, Malats N, Mengual L, Verhaegh G, Zeegers MP, Kiemeney LALM, Vermeulen SH. Eur Urol Oncol. 2022 Feb;5(1):70-83. doi: 10.1016/j.euo. 2021.07.001. Epub 2021 Aug 2. PMID: 34353775
Risk of bladder cancer death in patients younger than 50 with non-muscle-invasive and muscle-invasive bladder cancer. Russell B, Liedberg F, Hagberg O, Ullén A, Söderkvist K, Ströck V, Aljabery F, Gårdmark T, Jerlström T, Sherif A, Holmberg L, Bryan RT, Enting D, Van Hemelrijck M. Scand J Urol. 2022 Feb;56(1):27-33. doi: 10.1080/21681805.2021.2002399. Epub 2021 Nov 13. PMID: 34775873
A Systematic Review of Outcome Reporting, Definition and Measurement Heterogeneity in Non-Muscle Invasive Bladder Cancer Effectiveness Trials of Adjuvant, Prophylactic Treatment After Transurethral Resection Veskimae E, Subbarayan S, Campi R, Carron D, Omar MI, Yuan C, Dimitropoulos K, Van Hemelrijck, M, Bryan RT, N'Dow J, Babjuk M, Alfred Witjes J, Sylvester R, Maclennan S. Bladder Cancer. 2021 May 25;7(2):221-241. doi: 10.3233/BLC-201510.
An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Lindskrog SV, Prip F, Lamy P, Taber A, Groeneveld CS, Birkenkamp-Demtröder K, Jensen JB, Strandgaard T, Nordentoft I, Christensen E, Sokac M, Birkbak NJ, Maretty L, Hermann GG, Petersen AC, Weyerer V, Grimm MO, Horstmann M, Sjödahl G, Höglund M, Steiniche T, Mogensen K, de Reyniès A, Nawroth R, Jordan B, Lin X, Dragicevic D, Ward DG, Goel A, Hurst CD, Raman JD, Warrick JI, Segersten U, Sikic D, van Kessel KEM, Maurer T, Meeks JJ, DeGraff DJ, Bryan RT, Knowles MA, Simic T, Hartmann A, Zwarthoff EC, Malmström PU, Malats N, Real FX, Dyrskjøt L. Nat Commun. 2021 Apr 16;12(1):2301. doi: 10.1038/s41467-021-22465-w. PMID: 33863885
High-intensity Focused Ultrasound for the Treatment of Prostate Cancer: A National Cohort Study Focusing on the Development of Stricture and Fistulae. Dosanjh A, Harvey P, Baldwin S, Mintz H, Evison F, Gallier S, Trudgill N, James ND, Sooriakumaran P, Patel P. Eur Urol Focus. 2021 Mar;7(2):340-346. doi: 10.1016/j.euf. 2019.11. 014. Epub 2020 Jan 7. PMID: 31924529
The experience of UK patients with bladder cancer during the COVID-19 pandemic: a survey-based snapshot. Spencer-Bowdage S, Russell B, Rigby J, O'Kelly J, Kelly P, Page M, Raw C, Allchorne P, Harper P, Crew J, Kockelbergh R, Knight A, Van Hemelrijck M, Bryan RT. BJU Int. 2021 Feb;127(2):179-181. doi: 10.1111/bju.15287. Epub 2020 Nov 16. PMID: 33124729
Scoping review protocol: bladder cancer in Nigeria: what are the gaps in clinical care and research? Kibaru J, Kotecha P, Iya AM, Russell B, Abdullahi M, Alhassan SU, Mustapha MI, Bryan RT, Van Hemelrijck M. BMJ Open. 2021 Jan 31;11(1):e041894. doi: 10.1136/bmjopen-2020-041894. PMID: 33518520
The need for supportive mental wellbeing interventions in bladder cancer patients: A systematic review of the literature. Bessa A, Rammant E, Enting D, Bryan RT, Shamim Khan M, Malde S, Nair R, Thurairaja R, Cahill F, Amery S, Smith S, Ahmed K, Russell B, Moss C, Chatterton K, Häggström C, Van Hemelrijck M. PLoS One. 2021 Jan 28;16(1):e0243136. doi: 10.1371/journal.pone.0243136. eCollection 2021. PMID: 33507907
Designing a Pragmatic Intervention to Help Improve the Bladder Cancer Patient Experience. Bessa A, Bosco C, Cahill F, Russell B, Fox L, Moss C, Wylie H, Haire A, Green S, Enting D, Khan S, Nair R, Thurairaja R, Chatterton K, Amery S, Peat N, Smith S, Spear S, Bryan RT, Frodsham L, Burke D, Rigby J, Makaroff L, Kelly P, Costin M, Häggström C, Van Hemelrijck M. Inquiry. 2021 Jan-Dec;58:469580211030217. doi: 10.1177/00469580211030217. PMID: 34271831
Do Learning Disabilities Affect Testicular Cancer Survival: A National Cohort Study Between 2001 and 2015. Afshar M, Patel HRH, De-Santis M, Tanner JR, O'Neill T, Evison F, James ND, Selby PJ, Patel P. Eur Urol Oncol. 2020 Dec;3(6):773-779. doi: 10.1016/j.euo.2018.12.008. Epub 2019 Jan 15. PMID: 31411979
Development and validation of a follow-up methodology for a randomised controlled trial, utilising routine clinical data as an alternative to traditional designs: a pilot study to assess the feasibility of use for the BladderPath trial. Mintz HP, Dosanjh A, Parsons HM, Hughes A, Jakeman A, Pope AM, Bryan RT; BladderPath trial management group, James ND, Patel P. Pilot Feasibility Stud. 2020 Oct 31;6(1):165. doi: 10.1186/s40814-020-00713-y. PMID: 33292682
Fruit consumption and the risk of bladder cancer: A pooled analysis by the Bladder Cancer Epidemiology and Nutritional Determinants Study. Jochems SHJ, Reulen RC, van Osch FHM, Witlox WJA, Goossens ME, Brinkman M, Giles GG, Milne RL, van den Brandt PA, White E, Weiderpass E, Huybrechts I, Hémon B, Agudo A, Bueno-de-Mesquita B, Cheng KK, van Schooten FJ, Bryan RT, Wesselius A, Zeegers MP. Int J Cancer. 2020 Oct 15;147(8):2091-2100. doi: 10.1002/ijc.33008. Epub 2020 Apr 28. PMID: 32285440
Aryloxy Diester Phosphonamidate Prodrugs of Phosphoantigens (ProPAgens) as Potent Activators of Vγ9/Vδ2 T-Cell Immune Responses. Kadri H, Taher TE, Xu Q, Sharif M, Ashby E, Bryan RT, Willcox BE, Mehellou Y. J Med Chem. 2020 Oct 8;63(19):11258-11270. doi: 10.1021/acs.jmedchem.0c01232. Epub 2020 Sep 29. PMID: 32930595
Editorial: Bladder Cancer - A Cinderella Cancer: Advances and Remaining Research Questions. Van Hemelrijck M, Patel P, Mouw KW. Front Oncol. 2020 Sep 4;10:1749. doi: 10.3389/fonc. 2020.01749. eCollection 2020. PMID: 33014863
The implementation and utility of patient screening logs in a multicentre randomised controlled oncology trial. Lewis R, Todd R, Newton M, Jones RJ, Wilson C, Donovan JL, Bryan RT, Birtle A, Hall E; POUT Trial Management Group. Trials. 2020 Jul 8;21(1):629. doi: 10.1186/s13063-020-04559-w. PMID: 32641097 Clinical Trial.
Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Birtle A, Johnson M, Chester J, Jones R, Dolling D, Bryan RT, Harris C, Winterbottom A, Blacker A, Catto JWF, Chakraborti P, Donovan JL, Elliott PA, French A, Jagdev S, Jenkins B, Keeley FX Jr, Kockelbergh R, Powles T, Wagstaff J, Wilson C, Todd R, Lewis R, Hall E. Lancet. 2020 Apr 18;395(10232):1268-1277. doi: 10.1016/S0140-6736(20)30415-3. Epub 2020 Mar 5. PMID: 32145825 Clinical Trial.
A Systematic Review and Meta-analysis of Delay in Radical Cystectomy and the Effect on Survival in Bladder Cancer Patients. Russell B, Liedberg F, Khan MS, Nair R, Thurairaja R, Malde S, Kumar P, Bryan RT, Van Hemelrijck M. Eur Urol Oncol. 2020 Apr;3(2):239-249. doi: 10.1016/j.euo.2019.09.008. Epub 2019 Oct 23. PMID: 31668714
External Replication of Urinary Bladder Cancer Prognostic Polymorphisms in the UK Biobank. Lipunova N, Wesselius A, Cheng KK, van Schooten FJ, Cazier JB, Bryan RT, Zeegers MP. Front Oncol. 2019 Oct 18;9:1082. doi: 10.3389/fonc.2019.01082. eCollection 2019. PMID: 31681611
Graham Roberts Study protocol: first 'trials within cohort study' for bladder cancer. Wylie H, Cahill F, Santaolalla A, Moss CL, Enting D, Amery S, Chatterton K, Khan MS, Bryan RT, Gillett C, Josephs D, Chowdhury S, Rudman S, Hughes S, Relton C, Van Hemelrijck M. BMJ Open. 2019 Sep 26;9(9):e029468. doi: 10.1136/bmjopen-2019-029468. PMID: 31558452
Switching Cancers: A Systematic Review Assessing the Role of Androgen Suppressive Therapy in Bladder Cancer. Kourbanhoussen K, McMartin C, Lodde M, Zlotta A, Bryan RT, Toren P. Eur Urol Focus. 2021 Sep;7(5):1044-1051. doi: 10.1016/j.euf.2020.10.002. Epub 2020 Oct 31. PMID: 33132108 Review.
MRE11A Isoform Expression Associated with Outcome Following Radiotherapy in Muscle-Invasive Bladder Cancer does not Alter Cell Survival and DNA Double-Strand Break Repair Following Ionising Radiation. Walker AK, Na J, Browning L, Humayun-Zakaria N, Zeegers MP, Cheng KK, James ND, Bryan RT, Arnold R, Kiltie AE. Bladder Cancer. 2019 Aug 16;5(2):147-157. doi: 10.3233/BLC-190209. PMID: 31942442
Chronic tyrosine kinase inhibitor (TKI) use in metastatic renal cell carcinoma (mRCC): can this lead to the adverse effect of hypogonadism? Afshar M, Patel HRH, Jain A, Kumar A, Patel P, James ND, Porfiri E. Expert Rev Anticancer Ther. 2019 Jun;19(6):529-532. doi: 10.1080/14737140.2019.1609355. Epub 2019 May 2. PMID: 30995130
Modeling the Complex Exposure History of Smoking in Predicting Bladder Cancer: A Pooled Analysis of 15 Case-Control Studies. van Osch FHM, Vlaanderen J, Jochems SHJ, Bosetti C, Polesel J, Porru S, Carta A, Golka K, Jiang X, Stern MC, Zhong WD, Kellen E, Pohlabeln H, Tang L, Marshall J, Steineck G, Karagas MR, Johnson KC, Zhang ZF, Taylor JA, La Vecchia C, Bryan RT, van Schooten FJ, Wesselius A, Zeegers MP. Epidemiology. 2019 May;30(3):458-465. doi: 10.1097/EDE.0000000000000964. PMID: 30601243
An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment. Jepson M, Elliott D, Conefrey C, Wade J, Rooshenas L, Wilson C, Beard D, Blazeby JM, Birtle A, Halliday A, Stein R, Donovan JL; CSAW study group; Chemorad study group; POUT study group; ACST-2 study group; OPTIMA prelim study group. J Clin Epidemiol. 2018 Jul;99:75-83. doi: 10.1016/j.jclinepi.2018.02.018. Epub 2018 Mar 2. PMID: 29505860
A Stratified Meta-Analysis of the Association between Exposure to Environmental Tobacco Smoke during Childhood and Adulthood and Urothelial Bladder Cancer Risk. van Osch FHM, Jochems SHJ, Wesselius A, van Schooten FJ, Bryan RT, Zeegers MP. Int J Environ Res Public Health. 2018 Mar 22;15(4):569. doi: 10.3390/ijerph15040569. PMID: 29565277
Impact of dietary patterns and the main food groups on mortality and recurrence in cancer survivors: a systematic review of current epidemiological literature. Jochems SHJ, Van Osch FHM, Bryan RT, Wesselius A, van Schooten FJ, Cheng KK, Zeegers MP. BMJ Open. 2018 Feb 19;8(2):e014530. doi: 10.1136/bmjopen-2016-014530. PMID: 29459359 Review.
HumanMethylation450K Array-Identified Biomarkers Predict Tumour Recurrence/Progression at Initial Diagnosis of High-risk Non-muscle Invasive Bladder Cancer. Kitchen MO, Bryan RT, Emes RD, Luscombe CJ, Cheng KK, Zeegers MP, James ND, Gommersall LM, Fryer AA. Biomark Cancer. 2018 Jan 8;10:1179299X17751920. doi: 10.1177/ 1179299X17751920. eCollection 2018. PMID: 29343995
Who is at risk of death from nephrectomy? An analysis of thirty-day mortality after 21 380 nephrectomies in 3 years of the British Association of Urological Surgeons (BAUS) National Nephrectomy Audit. Fernando A, Fowler S, Van Hemelrijck M, O'Brien T; British Association of Urological Surgeons (BAUS). BJU Int. 2017 Sep;120(3):358-364. doi: 10.1111/bju.13842. Epub 2017 Apr 24. PMID: 28440053
Integrated Care in Prostate Cancer (ICARE-P): Nonrandomized Controlled Feasibility Study of Online Holistic Needs Assessment, Linking the Patient and the Health Care Team. Nanton V, Appleton R, Dale J, Roscoe J, Hamborg T, Ahmedzai SH, Arvanitis TN, Badger D, James N, Mendelsohn R, Khan O, Parashar D, Patel P. JMIR Res Protoc. 2017 Jul 28;6(7):e147. doi: 10.2196/resprot.7667. PMID: 28754653
UroMark-a urinary biomarker assay for the detection of bladder cancer. Feber A, Dhami P, Dong L, de Winter P, Tan WS, Martínez-Fernández M, Paul DS, Hynes-Allen A, Rezaee S, Gurung P, Rodney S, Mehmood A, Villacampa F, de la Rosa F, Jameson C, Cheng KK, Zeegers MP, Bryan RT, James ND, Paramio JM, Freeman A, Beck S, Kelly JD. Clin Epigenetics. 2017 Jan 31;9:8. doi: 10.1186/s13148-016-0303-5. eCollection 2017. PMID: 28163793
The Clinical Research Office of the Endourological Society (CROES) Multicentre Randomised Trial of Narrow Band Imaging-Assisted Transurethral Resection of Bladder Tumour (TURBT) Versus Conventional White Light Imaging-Assisted TURBT in Primary Non-Muscle-invasive Bladder Cancer Patients: Trial Protocol and 1-year Results. Naito S, Algaba F, Babjuk M, Bryan RT, Sun YH, Valiquette L, de la Rosette J; CROES Narrow Band Imaging Global Study Group. Eur Urol. 2016 Sep;70(3):506-15. doi: 10.1016/j.eururo. 2016.03.053. Epub 2016 Apr 23. PMID: 27117749 Clinical Trial.
Quantified relations between exposure to tobacco smoking and bladder cancer risk: a meta-analysis of 89 observational studies. van Osch FH, Jochems SH, van Schooten FJ, Bryan RT, Zeegers MP. Int J Epidemiol. 2016 Jun;45(3):857-70. doi: 10.1093/ije/dyw044. Epub 2016 Apr 20. PMID: 27097748
Significant Role of Lifetime Cigarette Smoking in Worsening Bladder Cancer and Upper Tract Urothelial Carcinoma Prognosis: A Meta-Analysis. van Osch FH, Jochems SH, van Schooten FJ, Bryan RT, Zeegers MP. J Urol. 2016 Apr;195(4 Pt 1):872-9. doi: 10.1016/j.juro.2015.10.139. Epub 2015 Oct 31. PMID: 26523878
Quantitative genome-wide methylation analysis of high-grade non-muscle invasive bladder cancer. Kitchen MO, Bryan RT, Emes RD, Glossop JR, Luscombe C, Cheng KK, Zeegers MP, James ND, Devall AJ, Mein CA, Gommersall L, Fryer AA, Farrell WE. Epigenetics. 2016 Mar 3;11(3):237-46. doi: 10.1080/15592294.2016.1154246. Epub 2016 Mar 1. PMID: 26929985
Methylation of HOXA9 and ISL1 Predicts Patient Outcome in High-Grade Non-Invasive Bladder Cancer. Kitchen MO, Bryan RT, Haworth KE, Emes RD, Luscombe C, Gommersall L, Cheng KK, Zeegers MP, James ND, Devall AJ, Fryer AA, Farrell WE. PLoS One. 2015 Sep 2;10(9):e0137003. doi: 10.1371/journal.pone.0137003. eCollection 2015. PMID: 26332997
Shifting paradigms in the estimation of survival for castration-resistant prostate cancer: A tertiary academic center experience. Afshar M, Evison F, James ND, Patel P. Urol Oncol. 2015 Aug;33(8):338.e1-7. doi: 10.1016/ j.urolonc.2015.05.003. Epub 2015 Jun 6. PMID: 26059077
Re: defining progression in nonmuscle invasive bladder cancer: it is time for a new, standard definition. D. Lamm, R. Persad, M. Brausi, R. Buckley, J. A. Witjes, J. Palou, A. Böhle, A. M. Kamat, M. Colombel and M. Soloway J Urol 2014;191:20-27. Bryan RT, Cheng KK, James ND, Zeegers MP, Wallace DM. J Urol. 2014 Jun;191(6):1930. doi: 10.1016/j.juro.2014.01.011. Epub 2014 Mar 11. PMID: 24625761
Expression of Engrailed-2 (EN2) protein in bladder cancer and its potential utility as a urinary diagnostic biomarker. Morgan R, Bryan RT, Javed S, Launchbury F, Zeegers MP, Cheng KK, James ND, Wallace DM, Hurst CD, Ward DG, Knowles MA, Pandha H. Eur J Cancer. 2013 Jun;49(9):2214-22. doi: 10.1016/j.ejca.2013.01.019. Epub 2013 Feb 21. PMID: 23434148
Antivector and tumor immune responses following adenovirus-directed enzyme prodrug therapy for the treatment of prostate cancer. Onion D, Patel P, Pineda RG, James N, Mautner V. Hum Gene Ther. 2009 Nov;20(11):1249-58. doi: 10.1089/hum.2009.078. PMID: 19619056 Clinical Trial.
A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954 [correction of CB1984]. Patel P, Young JG, Mautner V, Ashdown D, Bonney S, Pineda RG, Collins SI, Searle PF, Hull D, Peers E, Chester J, Wallace DM, Doherty A, Leung H, Young LS, James ND. Mol Ther. 2009 Jul;17(7):1292-9. doi: 10.1038/mt.2009.80. Epub 2009 Apr 14. PMID: 19367257 Clinical Trial.
Is gene therapy the answer for prostate cancer? Patel P, Ashdown D, James N. Prostate Cancer Prostatic Dis. 2004 Sep;7 Suppl 1:S14-9. doi: 10.1038/sj.pcan.4500743. PMID: 15365577

Connecting Cultures

Life-Changing Technologies

Thriving Planet

Global Health

Fairer World

Explore our Spotlights

Principal publications

Bladder Cancer Research Centre-led original research

Bladder Cancer Research Centre-led reviews and editorials

BCRC research with partners and collaborators